Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic obstructive pulmonary disease (COPD). The study did not meet its primary and secondary endpoints. There were no safety signals observed during the study. The company would like to thank the…
ISO 37001:2016 Certification: Chiesi Farmaceutici Starts the Extension Process of the Certification to the Affiliates of the Group As part of our commitment to preventing bribery and in accordance to the highest standards of compliance, Chiesi Farmaceutici has decided to start the extension process…
At Chiesi, we are committed to creating workspaces that prioritize both environmental sustainability and the well-being of those who inhabit them. The company aims to provide buildings that not only minimize their environmental impact but also foster healthy, productive environments for the people…
Today marks the one-year anniversary of the passing of Dr. Paolo Chiesi, former Honorary President of Chiesi Group. Dr. Paolo Chiesi was a visionary leader and a cornerstone of Chiesi Group for almost sixty years. His contributions to scientific progress and innovation have left a lasting impact on…
As part of our ongoing commitment to sustainability, Chiesi has updated its Code of Interdependence, aligning it with the latest industry standards and best practices. By focusing on the Sustainable Development Goals (SDGs) where we and our partners can have the greatest impact, we actively…
For the second consecutive year, Chiesi Group has been awarded the Platinum Medal by EcoVadis, ranking among the top 1% of companies worldwide for outstanding performance in Environment, Ethics, Labor and Human Rights, and Sustainable Procurement. This achievement, which reflects a five-point…
In a significant advancement in its commitment to combating climate change and promoting sustainability, Chiesi Group is proud to announce that the Science Based Targets initiative (SBTi) has validated its near- and long-term science-based emissions reduction targets, establishing a net-zero goal by…
Collaboration, co-creation and the exchange of ideas were at the heart of the Code of Interdependence workshop. The event was an opportunity to strengthen the Chiesi Group's strategic collaboration and to promote innovative solutions from the perspective of Chiesi's partners. The Code of…
Eight abstracts from Chiesi’s global respiratory research portfolio will be presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego starting from May 17, 2024. Presentations include preclinical and clinical stage global studies in asthma, Chronic Obstructive…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
